A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed Prophylactic Migraine Treatments

Trial Profile

A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed Prophylactic Migraine Treatments

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2018

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms LIBERTY
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 17 May 2018 According to a Novartis media release, the U.S. Food and Drug Administration (FDA) has approved Aimovig for the preventive treatment of migraine in adults.
    • 17 Apr 2018 Results presented in the Novartis media release.
    • 17 Apr 2018 According to Amgen media release, The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 17, 2018, for Aimovig and the European Medicines Agency has validated the Marketing Authorization Application (MAA) for Aimovig
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top